Post-earnings recap
Reported
Thu, Jul 27, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
United Therapeutics reported a strong EPS performance, exceeding expectations by over 17%. However, the stock fell nearly 5% in reaction, likely due to the absence of revenue figures and any forward guidance. Investors may be cautious given the lack of clarity on future performance and competitive pressures mentioned during the call.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $4.37 | N/A | +17.04% |
| Revenue | N/A | N/A | N/A |
Management expressed a commitment to innovation and addressing market challenges. However, they did not provide updated guidance, leaving some uncertainty.
Management highlighted ongoing efforts in product development.
They acknowledged competitive pressures in the market.
No specific guidance was provided for future quarters.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—